Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.

Chandrasekar P, Sirohi B, Seibel NL, Hsu JW, Azie N, Wu C, Ruhnke M.

Mycoses. 2018 May;61(5):331-336. doi: 10.1111/myc.12748. Epub 2018 Feb 2.

PMID:
29364548
2.

Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4.

Groll AH, Townsend R, Desai A, Azie N, Jones M, Engelhardt M, Schmitt-Hoffman AH, Brüggemann RJM.

Transpl Infect Dis. 2017 Oct;19(5). doi: 10.1111/tid.12751. Epub 2017 Sep 28. Review.

PMID:
28722255
3.

Candidemia and invasive candidiasis among hospitalized neonates and pediatric patients.

Harrington R, Kindermann SL, Hou Q, Taylor RJ, Azie N, Horn DL.

Curr Med Res Opin. 2017 Oct;33(10):1803-1812. doi: 10.1080/03007995.2017.1354824. Epub 2017 Aug 22.

PMID:
28699797
4.

A Risk Score for Fluconazole Failure among Patients with Candidemia.

Ostrosky-Zeichner L, Harrington R, Azie N, Yang H, Li N, Zhao J, Koo V, Wu EQ.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02091-16. doi: 10.1128/AAC.02091-16. Print 2017 May.

5.

Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis.

Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, Wu EQ, Spalding J.

Adv Ther. 2017 Jan;34(1):207-220. doi: 10.1007/s12325-016-0443-1. Epub 2016 Dec 2.

6.

Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study.

Kontoyiannis DP, Yang H, Song J, Kelkar SS, Yang X, Azie N, Harrington R, Fan A, Lee E, Spalding JR.

BMC Infect Dis. 2016 Dec 1;16(1):730.

7.

Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.

Gebremariam T, Wiederhold NP, Alqarihi A, Uppuluri P, Azie N, Edwards JE Jr, Ibrahim AS.

J Antimicrob Chemother. 2017 Feb;72(2):462-466. doi: 10.1093/jac/dkw433. Epub 2016 Oct 24.

8.

Epidemiological features of invasive mold infections among solid organ transplant recipients: PATH Alliance® registry analysis.

Husain S, Silveira FP, Azie N, Franks B, Horn D.

Med Mycol. 2017 Apr 1;55(3):269-277. doi: 10.1093/mmy/myw086.

PMID:
27703022
9.

Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.

Thompson GR 3rd, Rendon A, Ribeiro Dos Santos R, Queiroz-Telles F, Ostrosky-Zeichner L, Azie N, Maher R, Lee M, Kovanda L, Engelhardt M, Vazquez JA, Cornely OA, Perfect JR.

Clin Infect Dis. 2016 Aug 1;63(3):356-62. doi: 10.1093/cid/ciw305. Epub 2016 May 11.

10.

Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients.

Andes D, Azie N, Yang H, Harrington R, Kelley C, Tan RD, Wu EQ, Franks B, Kristy R, Lee E, Khandelwal N, Spalding J.

Antimicrob Agents Chemother. 2016 May 23;60(6):3398-406. doi: 10.1128/AAC.00054-16. Print 2016 Jun.

11.

Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial.

Horn D, Goff D, Khandelwal N, Spalding J, Azie N, Shi F, Franks B, Shorr AF.

J Med Econ. 2016 Jul;19(7):728-34. doi: 10.3111/13696998.2016.1164175. Epub 2016 Mar 30.

PMID:
26960060
12.

Development of New Strategies for Echinocandins: Progress in Translational Research.

Walsh TJ, Azie N, Andes DR.

Clin Infect Dis. 2015 Dec 1;61 Suppl 6:S601-3. doi: 10.1093/cid/civ676.

PMID:
26567276
13.

Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic/Pharmacodynamic Study with Humanized Doses in Mice.

Lepak A, Marchillo K, VanHecker J, Azie N, Andes D.

Antimicrob Agents Chemother. 2015 Nov 9;60(1):674-7. doi: 10.1128/AAC.02124-15. Print 2016 Jan.

14.
15.

Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents.

Hope WW, Kaibara A, Roy M, Arrieta A, Azie N, Kovanda LL, Benjamin DK Jr.

Antimicrob Agents Chemother. 2015 Feb;59(2):905-13. doi: 10.1128/AAC.03736-14. Epub 2014 Nov 24.

16.

Pharmacokinetic and safety profiles of repeated-dose prophylactic micafungin in children and adolescents undergoing hematopoietic stem cell transplantation.

Albano E, Azie N, Roy M, Townsend R, Arrieta A.

J Pediatr Hematol Oncol. 2015 Jan;37(1):e45-50. doi: 10.1097/MPH.0000000000000218.

PMID:
25072363
17.

Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008.

Pfaller MA, Andes DR, Diekema DJ, Horn DL, Reboli AC, Rotstein C, Franks B, Azie NE.

PLoS One. 2014 Jul 3;9(7):e101510. doi: 10.1371/journal.pone.0101510. eCollection 2014.

18.

Treatment and outcomes of invasive fusariosis: review of 65 cases from the PATH Alliance(®) registry.

Horn DL, Freifeld AG, Schuster MG, Azie NE, Franks B, Kauffman CA.

Mycoses. 2014 Nov;57(11):652-8. doi: 10.1111/myc.12212. Epub 2014 Jun 18.

19.

Clinical characteristics and outcomes in 303 HIV-infected patients with invasive fungal infections: data from the Prospective Antifungal Therapy Alliance registry, a multicenter, observational study.

Marukutira T, Huprikar S, Azie N, Quan SP, Meier-Kriesche HU, Horn DL.

HIV AIDS (Auckl). 2014 Mar 13;6:39-47. doi: 10.2147/HIV.S53910. eCollection 2014.

20.

The Prospective Antifungal Therapy Alliance(®) registry: A two-centre Canadian experience.

Haider S, Rotstein C, Horn D, Laverdiere M, Azie N.

Can J Infect Dis Med Microbiol. 2014 Spring;25(1):17-23.

21.

Prospective antifungal therapy (PATH) alliance(®) : focus on mucormycosis.

Kontoyiannis DP, Azie N, Franks B, Horn DL.

Mycoses. 2014 Apr;57(4):240-6. doi: 10.1111/myc.12149. Epub 2013 Oct 22.

PMID:
24147728
22.

Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasis.

Benjamin DK Jr, Deville JG, Azie N, Kovanda L, Roy M, Wu C, Arrieta A.

Pediatr Infect Dis J. 2013 Nov;32(11):e419-25. doi: 10.1097/INF.0b013e31829efd14.

23.

Treatment and outcomes of Candida osteomyelitis: review of 53 cases from the PATH Alliance® registry.

Neofytos D, Huprikar S, Reboli A, Schuster M, Azie N, Franks B, Horn D.

Eur J Clin Microbiol Infect Dis. 2014 Jan;33(1):135-41. doi: 10.1007/s10096-013-1939-0. Epub 2013 Aug 2.

PMID:
23907587
24.

Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004-2008.

Pfaller M, Neofytos D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, Horn D.

Diagn Microbiol Infect Dis. 2012 Dec;74(4):323-31. doi: 10.1016/j.diagmicrobio.2012.10.003. Epub 2012 Oct 25. Review.

PMID:
23102556
25.

Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry.

Steinbach WJ, Marr KA, Anaissie EJ, Azie N, Quan SP, Meier-Kriesche HU, Apewokin S, Horn DL.

J Infect. 2012 Nov;65(5):453-64. doi: 10.1016/j.jinf.2012.08.003. Epub 2012 Aug 13.

PMID:
22898389
26.

Rare diseases: the bane of modern society and the quest for cures.

Azie N, Vincent J.

Clin Pharmacol Ther. 2012 Aug;92(2):135-9. doi: 10.1038/clpt.2012.97.

PMID:
22814654
27.

The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012.

Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP, Horn D.

Diagn Microbiol Infect Dis. 2012 Aug;73(4):293-300. doi: 10.1016/j.diagmicrobio.2012.06.012. Review.

PMID:
22789847
28.

Comparing methods of measurement for detecting drug-induced changes in the QT interval: implications for thoroughly conducted ECG studies.

Azie NE, Adams G, Darpo B, Francom SF, Polasek EC, Wisser JM, Fleishaker JC.

Ann Noninvasive Electrocardiol. 2004 Apr;9(2):166-74.

PMID:
15084215
29.
30.

Single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers.

Rodríguez CA, Azie NE, Adams G, Donaldson K, Francom SF, Staton BA, Bombardt PA.

J Clin Pharmacol. 2004 Mar;44(3):276-83.

PMID:
14973308
31.

Interaction between ketoconazole and almotriptan in healthy volunteers.

Fleishaker JC, Herman BD, Carel BJ, Azie NE.

J Clin Pharmacol. 2003 Apr;43(4):423-7.

PMID:
12723463
32.

Cardiovascular effect of almotriptan in treated hypertensive patients.

Fleishaker JC, McEnroe JD, Azie NE, Francom SF, Carel BJ.

Clin Pharmacol Ther. 2002 Mar;71(3):169-75.

PMID:
11907491
33.

Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine.

Gomez-Mancilla B, Cutler NR, Leibowitz MT, Spierings EL, Klapper JA, Diamond S, Goldstein J, Smith T, Couch JR, Fleishaker J, Azie N, Blunt DE.

Cephalalgia. 2001 Sep;21(7):727-32.

PMID:
11595000
34.

Lack of effect of reboxetine on cardiac repolarization.

Fleishaker JC, Francom SF, Herman BD, Knuth DW, Azie NE.

Clin Pharmacol Ther. 2001 Sep;70(3):261-9.

PMID:
11557914
35.

Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans.

Fleishaker JC, Ryan KK, Jansat JM, Carel BJ, Bell DJ, Burke MT, Azie NE.

Br J Clin Pharmacol. 2001 May;51(5):437-41.

36.

Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers.

Fleishaker JC, Sisson TA, Carel BJ, Azie NE.

Cephalalgia. 2001 Feb;21(1):61-5.

PMID:
11298665
37.

Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers.

Fleishaker JC, Ryan KK, Carel BJ, Azie NE.

J Clin Pharmacol. 2001 Feb;41(2):217-23.

PMID:
11210405
38.

Intravenous diltiazem and CYP3A-mediated metabolism.

Masica AL, Azie NE, Brater DC, Hall SD, Jones DR.

Br J Clin Pharmacol. 2000 Sep;50(3):273-6.

39.

Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers.

Fleishaker JC, Sisson TA, Carel BJ, Azie NE.

Clin Pharmacol Ther. 2000 May;67(5):498-503.

PMID:
10824628
40.

Pharmacokinetics and tolerability of a novel 5-HT1D agonist, PNU-142633F.

Fleishaker JC, Pearson LK, Knuth DW, Gomez-Mancilla B, Francom SF, McIntosh MJ, Freestone S, Azie NE.

Int J Clin Pharmacol Ther. 1999 Oct;37(10):487-92.

PMID:
10543315
41.

The interaction of diltiazem with lovastatin and pravastatin.

Azie NE, Brater DC, Becker PA, Jones DR, Hall SD.

Clin Pharmacol Ther. 1998 Oct;64(4):369-77.

PMID:
9797793

Supplemental Content

Support Center